


Using the Variable-Nearest Neighbor Method To Identify P-Glycoprotein Substrates and Inhibitors

Patric Schyman,* Ruifeng Liu, and Anders Wallqvist*

DoD Biotechnology High Performance Computing Software Applications Institute, Telemedicine and Advanced Technology Research Center, US Army Medical Research and Materiel Command, Fort Detrick, Maryland 21702, United States

Supporting Information

ABSTRACT: Permeability glycoprotein (Pgp) is an essential membrane-bound transporter that efficiently extracts compounds from a cell. As such, it is a critical determinant of the pharmacokinetic properties of drugs. Multidrug resistance in cancer is often associated with overexpression of Pgp, which increases the efflux of chemotherapeutic agents from the cell. This, in turn, may prevent an effective treatment by reducing the effective intracellular concentrations of such agents. Consequently, identifying compounds that can either be transported out of the cell by Pgp (substrates) or impair Pgp function (inhibitors) is of great interest. Herein, using publically available data, we developed quantitative structure–activity relationship (QSAR) models of Pgp substrates and inhibitors. These models employed a variable-nearest neighbor (v-NN) method that calculated the structural similarity between molecules and hence possessed an applicability domain, that is, they used all nearest neighbors that met a minimum similarity constraint. The performance characteristics of these v-NN-based models were comparable or at times superior to those of other model constructs. The best v-NN models for identifying either Pgp substrates or inhibitors showed overall accuracies of >80% and κ values of >0.60 when tested on external data sets with candidate Pgp substrates and inhibitors. The v-NN prediction model with a well-defined applicability domain gave accurate and reliable results. The v-NN method is computationally efficient and requires no retraining of the prediction model when new assay information becomes available—an important feature when keeping QSAR models up-to-date and maintaining their performance at high levels.



INTRODUCTION

Permeability glycoprotein (Pgp), a member of the ATP-binding cassette (ABC) transporter family, is an important cell-membrane protein that regulates the efflux of foreign substances out of the cell.^{1–3} Pgp primarily exports hydrophobic compounds via an ATP-dependent process³ (Scheme 1). Compounds that interact with Pgp can be classified into three categories: substrates, inhibitors, and modulators.⁴ Pgp causes substrates to undergo efflux from the cell. By contrast, modulators and inhibitors both impair Pgp function; hence, these terms are often used synonymously. As shown in Scheme 1, the three most common ways to reduce Pgp function are (i) to block or competitively antagonize the substrate from attaching to the binding site (square), (ii) to inhibit the ATP binding site (triangle), and (iii) to interfere with the hydrolysis of ATP to ADP + P_i (star).

In cultured cancer cell lines and tumor models, overexpression of Pgp generates drug-resistant phenotypes.² Pgp overexpression is a major factor that contributes to multidrug resistance (MDR), a phenomenon in which cells develop tolerance to drugs even at lethal doses by pumping them out, thereby reducing their cytotoxic effect.³ MDR is of great concern because it is one of the major reasons for the failure of cancer chemotherapy treatments, of which paclitaxel administration is perhaps one of the best-known examples.

Considerable effort is also being devoted to identifying Pgp inhibitors that reduce drug resistance and improve drug effectiveness.^{6,7} Several experimental assays, including the monolayer efflux, calcein-AM, and ATPase assays,^{8,9} are available for assessing the compound transport across cellular membranes. These assays, however, are resource intensive. In this context, *in silico* models that identify inhibitors and substrates offer a valuable alternative for early prescreening efforts to guide the selection of compounds for experimental evaluation.


Several computational models have been proposed to predict the likelihood that a compound is a Pgp inhibitor^{10–15} or a substrate.^{15–17} Most of these models were developed using relatively small data sets, with concomitant limitations in their reliability. As such, the predictions of the models developed thus far are often difficult to validate. One aim of this study was to address this issue. We defined an applicability domain based on the premise that similar molecules have similar activities. In this way, we attempted to ensure that the models made a prediction only when a test molecule was similar to any of the molecules in the set of training compounds.

Received: September 15, 2016

Accepted: October 28, 2016

Published: November 16, 2016

Scheme 1. Illustration of the Drug Efflux Mediated by ATP-Driven Pgp Transport^a



^a(i) Drug binds to the substrate binding site (■),⁵ (ii) ATP binds to the ATP-binding site (▲), and (iii) hydrolysis of ATP to ADP + P_i (★). Although only one binding site is shown for simplicity, multiple binding sites could contribute to substrate promiscuity.

We also sought to test the utility of models that use an applicability domain in predicting Pgp substrates. As noted above, Pgp substrates are likely to be crucial for MDR because drugs that are Pgp substrates will accumulate less in cells than those that are not. This is why identifying Pgp substrates is often part of the early drug discovery screening process.¹⁸ Yet, despite the efforts that have been devoted to predicting Pgp inhibitors, the prediction of Pgp substrates themselves has received little attention. Predicting Pgp substrates is more challenging than predicting Pgp inhibitors because their

structural variability is likely to be high, given the crucial role of Pgp in removing foreign substances from cells.

Here, we used our versatile variable-nearest neighbor (*v*-NN) method¹⁹ to develop the Pgp substrate and inhibitor identification models and compared how they performed in relation to previously published model constructs. We also combined the data sets from Chen et al.¹² and Broccatelli et al.¹⁰ to develop a *v*-NN Pgp inhibitor model and analyzed its performance. Our results show that these *v*-NN models perform well and suggest that reliable predictions can easily be made with the use of an applicability domain.

RESULTS AND DISCUSSION

Prediction of Pgp Substrates. We applied our *v*-NN method to construct a Pgp substrate model, using experimentally determined substrates and nonsubstrates. The *v*-NN model predicts whether a test molecule is a substrate or a nonsubstrate on the premise that similar molecules have similar biological activities. If a test molecule is highly similar to a reference substrate molecule, it will be classified as a substrate. To increase the level of confidence in our predictions, we defined an applicability domain for the *v*-NN model by introducing a similarity threshold value (Tanimoto-distance threshold d_0) that had to be met to make a prediction. We selected the two *v*-NN parameters in eq 1 (smoothing factor h and Tanimoto-distance threshold d_0), according to the performance on the training set with respect to the κ value and overall coverage. We evaluated the performance of the model using the 10-fold cross validation, in which we randomly grouped the data set into ten equally sized groups and then used nine of the groups to construct the model and one to validate it. Subsequently, this process was repeated ten times so




Figure 1. Performance measures of the *v*-NN Pgp substrate model as a function of the Tanimoto-distance threshold d_0 at a constant smoothing factor h of 0.6 (a) and as a function of the smoothing factor h at a constant Tanimoto-distance threshold d_0 of 1.0 (b), evaluated using the 10-fold cross validation.

Table 1. Performance Measures in Predicting Pgp Substrates by Using the Data Set of Li et al.¹⁶

method	parameters	accuracy	sensitivity	specificity	κ	coverage
Training ^a						
v-NN	HC ($h = 0.3$; $d_0 = 1.0$) ^b	0.71	0.78	0.65	0.42	1.00
v-NN	HA ($h = 0.6$; $d_0 = 0.6$)	0.77	0.78	0.75	0.53	0.60
BC	ECFP10 + 8MP ^c	0.72	0.65	0.79	0.44	1.00
Test						
v-NN	HC ($h = 0.3$; $d_0 = 1.0$)	0.76	0.80	0.71	0.51	1.00
v-NN	HA ($h = 0.6$; $d_0 = 0.6$)	0.81	0.82	0.78	0.60	0.70
BC	ECFP10 + 8MP	0.73	0.66	0.81	0.47	1.00
Randomized Training Data ^d						
v-NN	HC ($h = 0.3$; $d_0 = 1.0$)	0.50	0.50	0.50	0.01	1.00
v-NN	HA ($h = 0.6$; $d_0 = 0.6$)	0.52	0.50	0.54	0.04	0.65

^aPerformance in a 10-fold cross validation. ^bv-NN parameters (smoothing factor, h , and Tanimoto-distance threshold, d_0). ^cBayesian classifier that employs ECFP10 fingerprints and eight molecular properties (MPs). ^dTraining set compounds for Pgp were randomly assigned as substrates or nonsubstrates.

that all groups were left out once, and the final result was reported as the average.

Figure 1a shows the performance measures of the model as a function of the Tanimoto-distance threshold d_0 at a constant smoothing factor h of 0.6. The best model performance, as measured by the κ value, was achieved at $d_0 = 0.2$, with an accuracy of 95%, sensitivity of 98%, specificity of 75%, and κ value of 0.77 (Figure 1a). However, this resulted in low coverage (9%), wherein the majority of compounds did not meet the Tanimoto-distance threshold.

A set of high-accuracy (HA) parameters ($h = 0.6$ and $d_0 = 0.6$; Figure 1a, arrow) was selected by adjusting the smoothing factor and the Tanimoto-distance threshold, which increased the coverage from 9 to 60%, while maintaining good performance measures (accuracy of 77%, sensitivity of 78%, specificity of 75%, and κ value of 0.53). In taking this approach, we sacrificed some coverage because we could not make predictions for 40% of the compounds. Although this inability may appear to be a limitation of our method, in our opinion, it is preferable not to make any prediction at all if these compounds are predicted merely by chance. Instead, these molecules should be tested experimentally. Once the results are known, the new data should then be included to the training set, so that the new model can make reliable predictions for similar compounds, effectively expanding the applicability domain of the model. Most published quantitative structure–activity relationship (QSAR) studies have not assessed the applicability domain of their models. Although this conveys the impression that these models are universally applicable, we and others have shown that the performance of a QSAR model rapidly deteriorates as new studies explore chemical spaces that differ from the space that was used to build the original model.^{20,21} This is one of the great challenges in QSAR development. In tackling this problem, we consider the use of an applicability domain as a necessary step to establish reliable in silico methods.

The coverage of a QSAR model can be increased by the v-NN approach in a straightforward fashion. Our v-NN Pgp substrate model achieved nearly 100% coverage when we increased the Tanimoto-distance threshold to 0.8 (Figure 1a). This came at the cost of inferior prediction performance, as indicated by the smaller κ values as well as the slightly lower accuracy and specificity. To ensure a fair comparison of the performance of our v-NN Pgp substrate model with that of previously proposed models, we increased the Tanimoto-

distance threshold to $d_0 = 1.0$ and varied the smoothing factor h to achieve a set of high-coverage (HC) parameters ($h = 0.3$ and $d_0 = 1.0$; Figure 1b, arrow) and enable our model to make predictions for all compounds.

To test the performance of the v-NN model in predicting Pgp substrates, we used the data set of Li et al.¹⁶ and their published Bayesian classifier (BC) model, which employs ECFP10 fingerprints and eight molecular properties (MPs). Table 1 summarizes the results of our v-NN model and the BC model. To compare the models directly, the table shows the model parameters with the 10-fold cross validation, the performance measures we calculated by using their data sets, and the BC model parameters reported by Li et al.

The best-performing v-NN model outperformed the BC + MP model with respect to accuracy, sensitivity, and κ value (Table 1). Of these three measures, high sensitivity is desirable because it assures high confidence in positive predictions. Even when we equated the v-NN model with the BC + MP model in terms of coverage (by using HC parameters), the sensitivity remained high in both the training and test sets, 0.78 and 0.80, respectively, compared with the corresponding sensitivities of 0.65 and 0.66 for the BC + MP model. However, the κ value is perhaps the most accurate measure for the performance of a prediction model because it takes into account the agreement occurring by chance. Although the v-NN model with the HC parameters performed on par with the BC + MP model on the training set with respect to the accuracy and the κ value, it performed better than the BC + MP model on the external test set. Furthermore, the v-NN model with the HA parameters showed superior accuracy and κ values on both the training and test sets.

To test the robustness of our model, we compared its performance when it was trained on the data set of Li et al. with that when it was trained on a randomized data set. As the bottom two rows of Table 1 show, the performance of the model deteriorated as expected. The accuracy, sensitivity, and specificity during randomized training were all approximately 0.5, a value much lower than the values during training with conventional data sets (0.65–0.78, top two rows of Table 1). In particular, the κ value was approximately zero, indicating that the model predictions were no better than those expected by chance. That our model is sensitive to relationships among compounds in the training data set suggests that it reliably predicts Pgp substrates.

Table 2. Performance Measures in Predicting Pgp Inhibitors by Using the Data Set of Broccatelli et al.¹⁰

method	parameters	accuracy	sensitivity	specificity	κ	coverage
Training^a						
v-NN	HC ($h = 0.2$; $d_0 = 1.0$) ^b	0.85	0.86	0.84	0.70	1.00
v-NN	HA ($h = 0.2$; $d_0 = 0.6$)	0.91	0.93	0.88	0.81	0.67
FLAP/VolSurf+		0.88	0.84	0.91	0.75	1.00
Internal Test						
v-NN	HC ($h = 0.2$; $d_0 = 1.0$)	0.84	0.84	0.83	0.67	1.00
v-NN	HA ($h = 0.2$; $d_0 = 0.6$)	0.89	0.88	0.91	0.78	0.66
FLAP/VolSurf+		0.85	0.82	0.87	0.69	1.00
External Test						
v-NN	HC ($h = 0.2$; $d_0 = 1.0$)	0.76	0.81	0.67	0.48	1.00
v-NN	HA ($h = 0.2$; $d_0 = 0.6$)	0.88	0.91	0.80	0.71	0.53
FLAP/VolSurf+		0.86	0.90	0.80	0.70	1.00
Randomized Training Data^c						
v-NN	HC ($h = 0.2$; $d_0 = 1.0$)	0.55	0.41	0.67	0.08	1.00
v-NN	HA ($h = 0.2$; $d_0 = 0.6$)	0.53	0.41	0.67	0.08	0.67

^aPerformance of 10-fold cross validation. ^bv-NN parameters (smoothing factor, h , and Tanimoto-distance threshold, d_0). ^cTraining set compounds for Pgp were randomly assigned as substrates or nonsubstrates.

Table 3. Performance Measures in Predicting Pgp Inhibitors by Using the Data set of Chen et al.¹²

method	parameters	accuracy	sensitivity	specificity	κ	coverage
Training^a						
v-NN	HC ($h = 0.1$; $d_0 = 1.0$) ^b	0.76	0.84	0.64	0.49	1.00
v-NN	HA ($h = 0.4$; $d_0 = 0.5$)	0.83	0.91	0.63	0.57	0.68
BC + MP	FCFP4 + 8 MP ^c	0.81	0.80	0.82	0.61	1.00
Test						
v-NN	HC ($h = 0.1$; $d_0 = 1.0$) ^a	0.76	0.87	0.59	0.48	1.00
v-NN	HA ($h = 0.4$; $d_0 = 0.5$)	0.80	0.91	0.50	0.45	0.72
BC + MP	FCFP4 + 8 MP	0.79	0.80	0.78	0.57	1.00
Randomized Training Data^d						
v-NN	HC ($h = 0.1$; $d_0 = 1.0$)	0.53	0.59	0.43	0.02	1.00
v-NN	HA ($h = 0.4$; $d_0 = 0.5$)	0.55	0.59	0.46	0.04	0.67

^aPerformance of LOO cross validation. ^bv-NN parameters (smoothing factor, h , and Tanimoto-distance threshold, d_0). ^cBayesian classifier that employs FCFP4 fingerprints and eight MPs. ^dTraining set compounds for Pgp were randomly assigned as substrates or nonsubstrates.

Prediction of Pgp Inhibitors. Following the modeling procedure we pursued when constructing the Pgp substrate model, we collected Pgp inhibitor data from the studies of Broccatelli et al.¹⁰ and Chen et al.¹² and analyzed them separately for comparison, before combining them into one large data set. Broccatelli et al. developed a model by employing a combination of molecular interaction field-based technologies and by considering pharmacophore features as well as physicochemical properties related to membrane partitioning. They used VolSurf+ descriptors²² to model the physicochemical properties and fingerprints for ligands and proteins (FLAP)²³ to identify the most important pharmacophore features.

Table 2 shows the results of the v-NN model and the FLAP/VolSurf+ model of Broccatelli et al. As in the case of predicting Pgp substrates, we determined two sets of v-NN parameters to achieve HC and HA via a series of 10-fold cross validations. We selected the v-NN HA parameters ($h = 0.2$ and $d_0 = 0.6$) to establish a limited applicability domain and thereby optimize the performance. This resulted in an excellent performance on the training set, with an accuracy of 91%, sensitivity of 93%, specificity of 88%, κ value of 0.81, and coverage of 67%. The HC parameters ($h = 0.2$ and $d_0 = 1.0$) allowed us to make a prediction for all molecules (100% coverage). The v-NN models performed well compared with the FLAP/VolSurf+

model on all three data sets (training, internal test, and external test). The v-NN model with the HA parameters gave the best performance and the most reliable result on all data sets.

We also compared the performance of our model when it was trained on the data set of Broccatelli et al. with that when it was trained on a randomized data set. The performance deteriorated as expected, and the low κ values indicated that the model predictions were no better than those expected by chance (bottom two rows of Table 2).

Table 3 compares the performance of v-NN models that used either HC parameters ($h = 0.1$ and $d_0 = 1.0$) or HA parameters ($h = 0.4$ and $d_0 = 0.5$) with that of the model developed by Chen et al.¹² using their data set. To directly compare our results with those of Chen et al., the training set was evaluated using the leave-one-out (LOO) cross validation instead of the 10-fold cross validation. Their model, which uses the BC model and eight molecular descriptors (BC + MP), performed as well as our v-NN models. The performance of the v-NN model with HA parameters was comparable to that of the BC + MP model, with an overall accuracy of 80%, sensitivity of 91%, and coverage of 72% for the test set. The v-NN models displayed excellent accuracy and sensitivity but showed low specificity. This may be attributed to our unbalanced data set, which included more Pgp inhibitors than noninhibitors. This asymmetry could have led to the low specificity of our models

Table 4. Performance Measures in Predicting Pgp Inhibitors by Using All Inhibitor Data

method	parameters	accuracy	sensitivity	specificity	κ	coverage
Training ^a						
v-NN	HC ($h = 0.1$; $d_0 = 1.0$) ^b	0.83	0.87	0.77	0.65	1.00
v-NN	HA ($h = 0.3$; $d_0 = 0.5$)	0.87	0.93	0.74	0.68	0.75
Evaluation						
v-NN	HC ($h = 0.1$; $d_0 = 1.0$)	0.77	0.88	0.66	0.54	1.00
v-NN	HA ($h = 0.3$; $d_0 = 0.5$)	0.81	0.92	0.69	0.62	0.81

^aPerformance of 10-fold cross validation. ^bv-NN parameters (smoothing factor, h , and Tanimoto-distance threshold, d_0).

by increasing their likelihood of falsely classifying a proportionally greater number of noninhibitors as inhibitors.

As in comparing the v-NN Pgp inhibitor model with a previous model by Broccatelli et al. (Table 2), we compared the performance of the former model when it was trained on the data set of Chen et al. with that when it was trained on a randomized data set. The performance again deteriorated as expected, and the low κ values indicated that the model predictions were no better than those expected by chance (bottom two rows of Table 3).

Prediction of Pgp Inhibitors in the Combined Data Set. The v-NN method relies on the diversity of the compounds used to construct the model. A large set of diverse molecules will result in a greater applicability domain of the model. We therefore combined the two inhibitor data sets into a single data set containing 1319 Pgp inhibitors and 957 noninhibitors. The data set was split into a training set of 1219 inhibitors and 857 noninhibitors and an evaluation set of 100 inhibitors and 100 noninhibitors. Table 4 shows the performance of the v-NN models in predicting Pgp inhibitors in this larger data set. The v-NN model with HA parameters ($h = 0.3$ and $d_0 = 0.5$) performed well on the training set as evaluated by the 10-fold cross validation, with an overall accuracy of 87% and a κ value of 0.68 in providing predictions for 75% of the compounds. The 75% coverage for the combined training set was greater than that achieved for the models constructed using only the data set of Broccatelli et al.¹⁰ or Chen et al.,¹² which showed coverage values of 67% and 68%, respectively (with the HA training values in Tables 2 and 3). On the evaluation set, the v-NN model generated predictions for 162 of the 200 compounds (81%) and correctly predicted 92% of the Pgp inhibitors. The v-NN model performed well even at 100% coverage, which was achieved by using the HC parameters ($h = 0.1$ and $d_0 = 1.0$); overall accuracies for the training and evaluation sets were 83 and 77%, respectively.

Klepsch et al.¹¹ also combined the data sets from Broccatelli et al.¹⁰ and Chen et al.¹² The models that performed best on their training set were the random forest (RF) and support vector machine (SVM) models, with overall accuracies of 86% and 75%, respectively. The corresponding accuracies of the RF and SVM models on their external test set were 75% and 73%, respectively. Klepsch et al. also presented a structure-based approach to predict Pgp inhibitors and noninhibitors by using the scoring function (ChemScore) in the docking program GOLD.²⁴ Even when they combined the scoring function with the logP value, they achieved only a total accuracy of 77%. This is lower than the accuracy of their ligand-based models. Although these results are comparable to our HC results, the v-NN model achieved higher accuracy with the HA parameters. We note, however, that their findings cannot be directly compared with our results because they used slightly different procedures for selecting their training and test sets.

Selectivity of the Pgp Substrate and Inhibitor Predictions.

Previous studies have investigated the MPs of Pgp substrates and inhibitors. Poongavanam et al.¹⁵ analyzed the occurrence of different functional groups and found that (1) Pgp substrates are typically amphipathic (i.e., possessing both hydrophobic and hydrophilic parts) and lipophilic, with three commonly occurring features: an aromatic system, an ether moiety, and an amine group; and (2) Pgp inhibitors are lipophilic and nonpolar, often containing an alkyl aryl ether, an aromatic amine, and a tertiary aliphatic amine group. Although Pgp substrates and inhibitors differ in some respects, they also share the property of being hydrophobic. If our assumption that similar molecules have similar MPs is correct and if the MPs of Pgp substrates differ distinctly from those of Pgp inhibitors, then v-NN models that perform well in predicting Pgp substrates should be poor at predicting Pgp inhibitors. Conversely, those predicting Pgp inhibitors should be poor at predicting Pgp substrates. Therefore, we tested whether the models developed to predict Pgp substrates would show poor performance when tested with Pgp inhibitors and vice versa. In both cases, the accuracy levels were $\sim 50\%$ and the κ values were close to zero (Figure 2). These results confirm that both the v-NN substrate and inhibitor models selectively identify the two different classes of Pgp compounds.




Figure 2. Prediction of substrates by using the v-NN Pgp inhibitor model and the prediction of inhibitors by using the v-NN Pgp substrate model, as evaluated by the 10-fold cross validation.

CONCLUSIONS

Our v-NN-based models outperformed current models in predicting Pgp substrates and performed comparably to methods such as FLAP/VolSurf+ in predicting Pgp inhibitors. The advantages of using the v-NN method are as follows: (i) reliable predictions by using an applicability domain to ensure that only compounds within the chemical space of the compounds used to construct the model are selected for

prediction and (ii) the absence of any need for retraining when new compounds are added to the model. We emphasize the importance of using a prediction model that is easily updated with new compound information and assay data, given our previous demonstration that feeding such models with even a small amount of assay data for truly novel compounds can greatly enhance their applicability domains.²⁰

METHODS

Pgp Data Sets. We used the Pgp substrate data collected by Hou and co-workers from monolayer efflux, ATPase activity, and rhodamine-123/calcein-AM fluorescence assays.¹⁶ This data set consists of measurements for a training set of 313 substrates and 309 nonsubstrates and those for a test set of 109 substrates and 91 nonsubstrates.

We extracted the data sets for Pgp inhibitors from Chen et al.¹² and Broccatelli et al.¹⁰ The data set from Chen et al. consists of measurements for a training set of 609 inhibitors and 393 noninhibitors and those for a test set of 188 inhibitors and 112 noninhibitors. The data set from Broccatelli et al. consists of measurements for three sets of compounds: (i) a training set of 334 inhibitors and 438 noninhibitors, (ii) an internal test set of 37 inhibitors and 47 noninhibitors, and (iii) an external test set of 274 inhibitors and 144 noninhibitors.

Combining the Pgp inhibitor data sets from Chen et al. and Broccatelli et al. and removing duplicates resulted in a combined data set consisting of a training set of 1219 inhibitors and 837 noninhibitors and an evaluation set of 100 inhibitors and 100 noninhibitors. All data sets and corresponding simplified molecular input line entry specifications (SMILES) are available in the [Supporting Information](#).

v-NN Method. The k-nearest neighbor (k-NN) method has been widely used to develop QSAR models.²⁵ This method rests on the premise that compounds with similar structures have similar activities. One difficulty with the k-NN method is that it always gives a prediction for a compound based on a constant number, k , of nearest neighbors regardless of the dissimilarity between the query and reference compounds. To correct for this shortcoming, we proposed a variable-nearest neighbor (v-NN) method¹⁹ that uses all nearest neighbors that meet a structural similarity criterion. When no nearest neighbor meets the criterion, the v-NN method makes no prediction. The predicted biological activity y is a weighted average across structurally similar neighbors

$$y = \frac{\sum_{i=1}^v y_i e^{-\left(\frac{d_i}{h}\right)^2}}{\sum_{i=1}^v e^{-\left(\frac{d_i}{h}\right)^2}} \quad d_i \leq d_0 \quad (1)$$

where d_i denotes the Tanimoto distance between a query molecule for which a prediction is made and a molecule i of the training set, y_i is the experimentally measured activity value of molecule i , v denotes the total number of molecules in the training set that satisfy the condition $d_i \leq d_0$, h is a smoothing factor that dampens the distance penalty, and d_0 is a Tanimoto-distance threshold beyond which two molecules are no longer considered to be sufficiently similar to be included in the average. The y_i values were set to 1 for predicting Pgp substrates or inhibitors and 0 for predicting nonsubstrates or noninhibitors. The v-NN method has two adjustable parameters that influence performance: the Tanimoto-distance threshold d_0 and the smoothing factor h . To identify structurally similar compounds, we used Accelrys extended-

connectivity fingerprints with a diameter of four chemical bonds (ECFP4).²⁶ We wish to emphasize that h and d_0 are unique and that they need to be optimized for each set of fingerprints. In this study, we tested the performance of three frequently used fingerprints: ECFP, FCFP, and MDL Public Keys.²⁷ We have included the performance measures of v-NN models that used different fingerprints in [Tables S8 and S9](#). All of the tested fingerprints allowed the v-NN model to perform well on the data sets, with comparable results. For this study, we chose the ECFP4 fingerprints that have previously been reported by Duan et al.²⁸ and Hert et al.²⁹ to show the best overall performance in retrieving the active compounds of many diverse data sets.

Model Performance Measures. We used the following metrics to measure the quality of the classification models

$$\text{Sensitivity} = \frac{\text{TP}}{\text{TP} + \text{FN}} \quad (2)$$

$$\text{Specificity} = \frac{\text{TN}}{\text{FP} + \text{TN}} \quad (3)$$

$$\text{Accuracy} = \frac{\text{TP} + \text{TN}}{\text{TP} + \text{TN} + \text{FP} + \text{FN}} \quad (4)$$

$$\kappa = \frac{\text{accuracy} - \text{Pr}(e)}{1 - \text{Pr}(e)} \quad (5)$$

where TP, TN, FP, and FN denote true positive, true negative, false positive, and false negative, respectively. κ is a metric for assessing the quality of binary classifiers. $\text{Pr}(e)$ is an estimate of the probability of a correct prediction by chance.³⁰ It is calculated as

$$\begin{aligned} \text{Pr}(e) &= \frac{(\text{TP} + \text{FN})(\text{TP} + \text{FP}) + (\text{FP} + \text{TN})(\text{TN} + \text{FN})}{(\text{TP} + \text{FN} + \text{FP} + \text{TN})^2} \end{aligned} \quad (6)$$

Sensitivity is a measure of a model's ability to correctly detect true positives, whereas specificity measures a model's ability to detect true negatives. κ compares the probability of correct predictions to the probability of correct predictions by chance. Its value ranges from +1 (perfect agreement between model prediction and experiment) to -1 (complete disagreement), with 0 indicating no agreement beyond that expected by chance.

We also calculated the coverage, which is defined as the proportion of test molecules with at least one nearest neighbor that exceeded the similarity criterion. The coverage is a measure of how many test compounds are within the applicability domain of a prediction model.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the [ACS Publications website](#) at DOI: [10.1021/acsomega.6b00247](https://doi.org/10.1021/acsomega.6b00247).

Computational details for optimizing v-NN parameters for HA and HC ([Tables S1–S7](#) and [Figures S1–S6](#)); Results on the v-NN method using different fingerprints ([Table S8](#) and [S9](#)) ([PDF](#))

Data sets and corresponding SMILES ([XLSX](#))

AUTHOR INFORMATION

Corresponding Authors

*E-mail: pschyman@bhsai.org (P.S.).

*E-mail: sven.a.wallqvist.civ@mail.mil. Phone: 301-619-1989. Fax: 301-619-1983 (A.W.).

Funding

The authors were supported by the US Army Medical Research and Materiel Command (Fort Detrick, MD) and the Defense Threat Reduction Agency grant CBCall14-CBS-05-2-0007.

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the US Army or of the US Department of Defense.

ABBREVIATIONS

ADP, adenosine diphosphate; ATP, adenosine triphosphate; BC, Bayesian classifier; ECFP, extended connectivity fingerprints; FCFP, functional connectivity fingerprints; FLAP, fingerprints for ligands and proteins; HA, high accuracy; HC, high coverage; MDR, multidrug resistance; MP, molecular properties; Pgp, permeability glycoprotein; QSAR, quantitative structure–activity relationship; v-NN, variable-nearest neighbor

REFERENCES

- (1) Ambudkar, S. V.; Kimchi-Sarfaty, C.; Sauna, Z. E.; Gottesman, M. M. P-Glycoprotein: From Genomics to Mechanism. *Oncogene* **2003**, *22*, 7468–7485.
- (2) Ueda, K.; Clark, D. P.; Chen, C. J.; Roninson, I. B.; Gottesman, M. M.; Pastan, I. The Human Multidrug Resistance (mdr1) Gene. cDNA Cloning and Transcription Initiation. *J. Biol. Chem.* **1987**, *262*, 505–508.
- (3) Borst, P.; Elferink, R. O. Mammalian ABC Transporters in Health and Disease. *Annu. Rev. Biochem.* **2002**, *71*, 537–592.
- (4) Colabufo, N. A.; Berardi, F.; Cantore, M.; Contino, M.; Inglesse, C.; Niso, M.; Perrone, R. Perspectives of P-Glycoprotein Modulating Agents in Oncology and Neurodegenerative Diseases: Pharmaceutical, Biological, and Diagnostic Potentials. *J. Med. Chem.* **2010**, *53*, 1883–1897.
- (5) Subramanian, N.; Condic-Jurkic, K.; O'Mara, M. L. Structural and dynamic perspectives on the promiscuous transport activity of P-glycoprotein. *Neurochem. Int.* **2016**, *98*, 146–152.
- (6) Abdallah, H. M.; Al-Abd, A. M.; El-Dine, R. S.; El-Halawany, A. M. P-Glycoprotein Inhibitors of Natural Origin as Potential Tumor Chemo-Sensitizers: A Review. *J. Adv. Res.* **2015**, *6*, 45–62.
- (7) Munagala, S.; Sirasani, G.; Kokkonda, P.; Phadke, M.; Krynetskaia, N.; Lu, P.; Sharom, F. J.; Chaudhury, S.; Abdulhameed, M. D. M.; Tawa, G.; Wallqvist, A.; Martinez, R.; Childers, W.; Abou-Gharbia, M.; Krynetskiy, E.; Andrade, R. B. Synthesis and Evaluation of Strychnos Alkaloids as MDR Reversal Agents for Cancer Cell Eradication. *Bioorg. Med. Chem.* **2014**, *22*, 1148–1155.
- (8) Adachi, Y.; Suzuki, H.; Sugiyama, Y. Comparative Studies on in Vitro Methods for Evaluating in Vivo Function of MDR1 P-Glycoprotein. *Pharm. Res.* **2001**, *18*, 1660–1668.
- (9) Feng, B.; Mills, J. B.; Davidson, R. E.; Mireles, R. J.; Janiszewski, J. S.; Troutman, M. D.; de Moraes, S. M. In Vitro P-Glycoprotein Assays to Predict the in Vivo Interactions of P-Glycoprotein with Drugs in the Central Nervous System. *Drug Metab. Dispos.* **2008**, *36*, 268–275.
- (10) Broccatelli, F.; Carosati, E.; Neri, A.; Frosini, M.; Goracci, L.; Oprea, T. I.; Cruciani, G. A Novel Approach for Predicting P-Glycoprotein (ABC1) Inhibition Using Molecular Interaction Fields. *J. Med. Chem.* **2011**, *54*, 1740–1751.
- (11) Klepsch, F.; Vasanthanathan, P.; Ecker, G. F. Ligand and Structure-Based Classification Models for Prediction of P-Glycoprotein Inhibitors. *J. Chem. Inf. Model.* **2014**, *54*, 218–229.
- (12) Chen, L.; Li, Y.; Zhao, Q.; Peng, H.; Hou, T. ADME Evaluation in Drug Discovery. 10. Predictions of P-Glycoprotein Inhibitors Using Recursive Partitioning and Naive Bayesian Classification Techniques. *Mol. Pharmaceutics* **2011**, *8*, 889–900.
- (13) Leong, M. K.; Chen, H.-B.; Shih, Y.-H. Prediction of Promiscuous P-Glycoprotein Inhibition Using a Novel Machine Learning Scheme. *PLoS One* **2012**, *7*, No. e33829.
- (14) Chen, L.; Li, Y.; Yu, H.; Zhang, L.; Hou, T. Computational Models for Predicting Substrates or Inhibitors of P-Glycoprotein. *Drug Discovery Today* **2012**, *17*, 343–351.
- (15) Poongavanam, V.; Haider, N.; Ecker, G. F. Fingerprint-Based In Silico Models for the Prediction of P-Glycoprotein Substrates and Inhibitors. *Bioorg. Med. Chem.* **2012**, *20*, 5388–5395.
- (16) Li, D.; Chen, L.; Li, Y.; Tian, S.; Sun, H.; Hou, T. ADMET Evaluation in Drug Discovery. 13. Development of in Silico Prediction Models for P-Glycoprotein Substrates. *Mol. Pharmaceutics* **2014**, *11*, 716–726.
- (17) Ekins, S.; Kim, R. B.; Leake, B. F.; Dantzig, A. H.; Schuetz, E. G.; Lan, L.-B.; Yasuda, K.; Shepard, R. L.; Winter, M. a.; Schuetz, J. D.; Wikel, J. H.; Wrighton, S. A. Application of Three-Dimensional Quantitative Structure-Activity Relationships of P-Glycoprotein Inhibitors and Substrates. *Mol. Pharmacol.* **2002**, *61*, 974–981.
- (18) Szakács, G.; Váradi, A.; Özvegy-Laczka, C.; Sarkadi, B. The Role of ABC Transporters in Drug Absorption, Distribution, Metabolism, Excretion and Toxicity (ADME-Tox). *Drug Discovery Today* **2008**, *13*, 379–393.
- (19) Liu, R.; Tawa, G.; Wallqvist, A. Locally Weighted Learning Methods for Predicting Dose-Dependent Toxicity with Application to the Human Maximum Recommended Daily Dose. *Chem. Res. Toxicol.* **2012**, *25*, 2216–2226.
- (20) Liu, R.; Schyman, P.; Wallqvist, A. Critically Assessing the Predictive Power of QSAR Models for Human Liver Microsomal Stability. *J. Chem. Inf. Model.* **2015**, *55*, 1566–1575.
- (21) Sheridan, R. P. Time-Split Cross-Validation as a Method for Estimating the Goodness of Prospective Prediction. *J. Chem. Inf. Model.* **2013**, *53*, 783–790.
- (22) Cruciani, G.; Crivori, P.; Carrupt, P.-A.; Testa, B. Molecular Fields in Quantitative Structure–Permeation Relationships: The VolSurf Approach. *J. Mol. Struct.: THEOCHEM* **2000**, *503*, 17–30.
- (23) Baroni, M.; Cruciani, G.; Sciabola, S.; Perruccio, F.; Mason, J. S. A Common Reference Framework for Analyzing/Comparing Proteins and Ligands. Fingerprints for Ligands And Proteins (FLAP): Theory and Application. *J. Chem. Inf. Model.* **2007**, *47*, 279–294.
- (24) Verdonk, M. L.; Chessari, G.; Cole, J. C.; Hartshorn, M. J.; Murray, C. W.; Nissink, J. W. M.; Taylor, R. D.; Taylor, R. Modeling Water Molecules in Protein–Ligand Docking Using GOLD. *J. Med. Chem.* **2005**, *48*, 6504–6515.
- (25) Zheng, W.; Tropsha, A. Novel Variable Selection Quantitative Structure–Property Relationship Approach Based on the k-Nearest-Neighbor Principle. *J. Chem. Inf. Model.* **2000**, *40*, 185–194.
- (26) Rogers, D.; Hahn, M. Extended-Connectivity Fingerprints. *J. Chem. Inf. Model.* **2010**, *50*, 742–754.
- (27) Durant, J. L.; Leland, B. A.; Henry, D. R.; Nourse, J. G. Reoptimization of MDL Keys for Use in Drug Discovery. *J. Chem. Inf. Model.* **2002**, *42*, 1273–1280.
- (28) Duan, J.; Dixon, S. L.; Lowrie, J. F.; Sherman, W. Analysis and comparison of 2D fingerprints: Insights into database screening performance using eight fingerprint methods. *J. Mol. Graphics Modell.* **2010**, *29*, 157–170.
- (29) Hert, J.; Willett, P.; Wilton, D. J.; Acklin, P.; Azaoui, K.; Jacoby, E.; Schuffenhauer, A. Comparison of topological descriptors for similarity-based virtual screening using multiple bioactive reference structures. *Org. Biomol. Chem.* **2004**, *2*, 3256–3266.
- (30) Dunn, G.; Everitt, B. *Clinical Biostatistics: An Introduction to Evidence-Based Medicine*; Edward Arnold: London, 1995.